Figure 2.

Effect of single-agent evofosfamide in IV metastatic model.

A and B show the effect of evofosfamide (Evo) treatment on liver and kidney after treatment for 14 days. The criteria assigning metastatic score in organs are: 0 (no metastasis), 1 (one or two metastases in entire organ), 2 (few scattered metastases), 3 (extensive metastases, but the organ has maintained its gross anatomic integrity), and 4 (extensive metastases affecting anatomic features of the organ). C indicates the Kaplan-Meier survival curve of mice treated with single-agent evofosfamide till the end point, where mean survival time for untreated control and evofosfamide-treated groups is 11 days and 24 days, respectively.